Evaluación:
(not yet rated) | Resumen | BNT162b2 is a nucleoside-modified RNA vaccine expressing the full-length prefusion spike glycoprotein (S) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In a randomized, placebo-controlled clinical trial involving approximately 44,000 participants, immunization conferred 95% efficacy against coronavirus disease 2019 (Covid-19). |
|---|---|
| Procedencia del autor |
| Texto completo |
|---|
| Tipo de documento | |
|---|---|
| Especialidad(es) |
| Publicado en el sitio | 2021-03-10 17:52:17 |
|---|
(aún no hay comentarios disponibles para este recurso)
Crear cuenta
Comentarios